Mel4 antimicrobial peptide-coated contact lenses show promise in reducing inflammation, reaching Phase III clinical trials

Approximately 150 million people worldwide wear contact lenses, yet this practice remains a significant risk factor for developing ocular infections and inflammation, including severe conditions like Acanthamoeba keratitis. Current preventative measures are often insufficient, leading to discomfort, vision loss, and the need for reactive treatments. There is a clear unmet need for proactive solutions, driving research into biomaterial-based strategies, particularly antimicrobial coatings, to enhance contact lens safety and reduce the incidence of microbial keratitis and associated inflammatory responses.

Researchers conducted a comprehensive review of biomaterial-based solutions for preventing contact lens-associated infections and inflammation. The review synthesized findings on various antimicrobial coatings, including antimicrobial peptides (AMPs), metals such as silver and selenium, and quorum sensing inhibitors. The authors evaluated the progression of these technologies through preclinical research and clinical trials, focusing on their efficacy in reducing infection and inflammation, and their potential for commercial translation.

The review identified antimicrobial peptides (AMPs) as a particularly well-researched class of antimicrobial coatings for contact lenses. Among these, Mel4 has demonstrated significant success, progressing to a successful stage III clinical trial. This trial specifically showed that Mel4-coated lenses reduced the incidence of contact lens-associated inflammation. Other antimicrobial strategies, including coatings incorporating metals like silver and selenium, and quorum sensing inhibitors, have also advanced through various stages of clinical trials. However, the review notes that:

Currently, only the Mel4-coated lenses have been shown to reduce the incidence of contact lens-associated inflammation, highlighting its unique efficacy in this specific outcome. Despite these promising advancements and the clear need for such products, no antimicrobial contact lens is yet commercially available for sale, indicating a gap between research success and market availability.